Given CCL5 is highly expressed by TAMs rather than prostate cancer cells, the combinational therapeutic strategy of blocking TAMs and neutralizing CCL5 may be a promising and powerful approach for PCSCs elimination in the future. The gene discussed is CCL5; the disease is prostate carcinoma.